Estrogen receptor α and β subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 94, Issue 1-3 SPEC. ISS., 2005, Pages 71-81

  Gougelet, Angélique ^a   Bouclier, Céline ^a   Marsaud, Véronique ^a   Maillard, Sébastien ^a   Mueller, Stefan O ^b   Korach, Kenneth S ^c   Renoir, Jack Michel ^a  

^a UNIV PARIS SUD   (France)

^b MERCK KGAA   (Germany)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Anti estrogens; Breast cancer cells; Estrogen receptors; hsp90 Inhibitors; Immunosuppressants; Proteasome; Transactivation

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL] ESTRADIOL; 11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 4 HYDROXYTAMOXIFEN; CYCLOPHILIN; CYCLOSPORIN A; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMMUNOPHILIN; NOVOBIOCIN; PROTEASOME; RADICICOL; RAPAMYCIN; STEROID RECEPTOR; TACROLIMUS; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE G1 PHASE; ESTROGEN RESPONSIVE ELEMENT; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSACTIVATION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 18144405740     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.01.018     Document Type: Article

References (59)

1. S. Nilsson, S. Makela, E. Treuter, M. Tujague, J. Thomsen, G. Andersson, E. Enmark, K. Pettersson, M. Warner, and J.A. Gustafsson Mechanisms of estrogen action Physiol. Rev. 81 2001 1535 1565
2. J.M. Hall, J.F. Couse, and K.S. Korach The multifaceted mechanisms of estradiol and estrogen receptor signaling J. Biol. Chem. 276 2001 36869 36872
3. J.I. MacGregor, and V.C. Jordan Basic guide to the mechanisms of antiestrogen action Pharmacol. Rev. 50 1998 151 196
4. J.M. Hall, D.P. McDonnell, and K.S. Korach Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements Mol. Endocrinol. 16 2002 469 486
5. J.M. Hall, and K.S. Korach Analysis of the molecular mechanisms of human estrogen receptors alpha and beta reveals differential specificity in target promoter regulation by xenoestrogens J. Biol. Chem. 277 2002 44455 44461
6. V.C. Jordan Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents J. Med. Chem. 46 2003 1081 1111
7. S. Somai, M. Chaouat, D. Jacob, J.Y. Perrot, W. Rostene, P. Forgez, and A. Gompel Antiestrogens are pro-apoptotic in normal human breast epithelial cells Int. J. Cancer 105 2003 607 612
8. K. Paech, P. Webb, G.G. Kuiper, S. Nilsson, J. Gustafsson, P.J. Kushner, and T.S. Scanlan Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites Science 277 1997 1508 1510
9. E.T. Alarid, N. Bakopoulos, and N. Solodin Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation Mol. Endocrinol. 13 1999 1522 1534
10. Z. Nawaz, D.M. Lonard, A.P. Dennis, C.L. Smith, and B.W. O'Malley Proteasome-dependent degradation of the human estrogen receptor Proc. Natl. Acad. Sci. U.S.A. 96 1999 1858 1862
11. A. El Khissiin, and G. Leclercq Implication of proteasome in estrogen receptor degradation FEBS Lett. 448 1999 160 166
12. D.M. Lonard, Z. Nawaz, C.L. Smith, and B.W. O'Malley The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation Mol. Cell 5 2000 939 948
13. A.L. Wijayaratne, and D.P. McDonnell The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators J. Biol. Chem. 276 2001 35684 35692
14. V. Marsaud, A. Gougelet, S. Maillard, and J.-M. Renoir Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells Mol. Endocrinol. 17 2003 2013 2027
15. D.L. Stenoien, K. Patel, M.G. Mancini, M. Dutertre, C.L. Smith, B.W. O'Malley, and M.A. Mancini FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent Nat. Cell. Biol. 3 2001 15 23
16. G.G. Kuiper, B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, S. Nilsson, and J.A. Gustafsson Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta Endocrinology 138 1997 863 870
17. S.O. Mueller, S. Simon, K. Chae, M. Metzler, and K.S. Korach Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells Toxicol. Sci. 80 2004 14 25
18. J.F. Couse, and K.S. Korach Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20 1999 358 417
19. L. Wang, S. Andersson, M. Warner, and J.A. Gustafsson Morphological abnormalities in the brains of estrogen receptor beta knockout mice Proc. Natl. Acad. Sci. U.S.A. 98 2001 2792 2796
20. K.S. Korach Insights from the study of animals lacking functional estrogen receptor Science 266 1994 1524 1527
21. W.P. Bocchinfuso, and K.S. Korach Mammary gland development and tumorigenesis in estrogen receptor knockout mice J. Mammary Gland Biol. Neoplasia 2 1997 323 334
22. J. An, C. Tzagarakis-Foster, T.C. Scharschmidt, N. Lomri, and D.C. Leitman Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens J. Biol. Chem. 276 2001 17808 17814
23. J.A. Gustafsson, and M. Warner Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer J. Steroid Biochem. Mol. Biol. 74 2000 245 248
24. J.M. Hall, and D.P. McDonnell The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens Endocrinology 140 1999 5566 5578
25. K. Pettersson, F. Delaunay, and J.A. Gustafsson Estrogen receptor beta acts as a dominant regulator of estrogen signaling Oncogene 19 2000 4970 4978
26. G. Lazennec, J.L. Alcorn, and B.S. Katzenellenbogen Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation Mol. Endocrinol. 13 1999 969 980
27. G. Lazennec, D. Bresson, A. Lucas, C. Chauveau, and F. Vignon ER beta inhibits proliferation and invasion of breast cancer cells Endocrinology 142 2001 4120 4130
28. M.M. Liu, C. Albanese, C.M. Anderson, K. Hilty, P. Webb, R.M. Uht, R.H. Price Jr., R.G. Pestell, and P.J. Kushner Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression J. Biol. Chem. 277 2002 24353 24360
29. S. Paruthiyil, H. Parmar, V. Kerekatte, G.R. Cunha, G.L. Firestone, and D.C. Leitman Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest Cancer Res. 64 2004 423 428
30. K. Iwao, Y. Miyoshi, C. Egawa, N. Ikeda, and S. Noguchi Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers Int. J. Cancer 88 2000 733 736
31. P. Roger, M.E. Sahla, S. Makela, J.A. Gustafsson, P. Baldet, and H. Rochefort Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors Cancer Res. 61 2001 2537 2541
32. W.B. Pratt, and D.O. Toft Steroid receptor interactions with heat shock protein and immunophilin chaperones Endocr. Rev. 18 1997 306 360
33. S.M. Roe, C. Prodromou, R. O'Brien, J.E. Ladbury, P.W. Piper, and L.H. Pearl Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin J. Med. Chem. 42 1999 260 266
34. A. Maloney, and P. Workman HSP90 as a new therapeutic target for cancer therapy: the story unfolds Expert Opin. Biol. Ther. 2 2002 3 24
35. S.O. Mueller, J.M. Hall, D.L. Swope, L.C. Pedersen, and K.S. Korach Molecular determinants of the stereo-selectivity of agonist activity of estrogen receptor (ER)alpha and ERbeta J. Biol. Chem. 2003
36. D. Gagne, P. Balaguer, E. Demirpence, C. Chabret, F. Trousse, J.C. Nicolas, and M. Pons Stable luciferase transfected cells for studying steroid receptor biological activity J. Biolumin. Chemilumin. 9 1994 201 209
37. I. Touitou, F. Vignon, V. Cavailles, and H. Rochefort Hormonal regulation of cathepsin D following transfection of the estrogen or progesterone receptor into three sex steroid hormone resistant cancer cell lines J. Steroid Biochem. Mol. Biol. 40 1991 231 237
38. O. Boussif, F. Lezoualc'h, M.A. Zanta, M.D. Mergny, D. Scherman, B. Demeneix, and J.P. Behr A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine Proc. Natl. Acad. Sci. U.S.A. 92 1995 7297 7301
39. F.J. Monsma Jr., B.S. Katzenellenbogen, M.A. Miller, Y.S. Ziegler, and J.A. Katzenellenbogen Characterization of the estrogen receptor and its dynamics in MCF-7 human breast cancer cells using a covalently attaching antiestrogen Endocrinology 115 1984 143 153
40. R. Metivier, G. Penot, M.R. Hubner, G. Reid, H. Brand, M. Kos, and F. Gannon Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter Cell 115 2003 751 763
41. B.K. Ward, P.J. Mark, D.M. Ingram, R.F. Minchin, and T. Ratajczak Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer Breast Cancer Res. Treat. 58 1999 267 280
42. J.S. Carroll, D.K. Lynch, A. Swarbrick, J.-M. Renoir, B. Sarcevic, R.J. Daly, E.A. Musgrove, and R.L. Sutherland p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells Cancer Res. 63 2003 4322 4326
43. R.U. Janicke, P. Ng, M.L. Sprengart, and A.G. Porter Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis J. Biol. Chem. 273 1998 15540 15545
44. L. Neckers, E. Mimnaugh, and T.W. Schulte Hsp90 as an anti-cancer target Drug Resist. Updat. 2 1999 165 172
45. D. Picard, B. Khursheed, M.J. Garabedian, M.G. Fortin, S. Lindquist, and K.R. Yamamoto Reduced levels of hsp90 compromise steroid receptor action in vivo Nature 348 1990 166 168
46. J.P. Grenert, W.P. Sullivan, P. Fadden, T.A. Haystead, J. Clark, E. Mimnaugh, H. Krutzsch, H.J. Ochel, T.W. Schulte, E. Sausville, L.M. Neckers, and D.O. Toft The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation J. Biol. Chem. 272 1997 23843 23850
47. C. Prodromou, S.M. Roe, R. O'Brien, J.E. Ladbury, P.W. Piper, and L.H. Pearl Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone Cell 90 1997 65 75
48. T. Scheibel, S. Neuhofen, T. Weikl, C. Mayr, J. Reinstein, P.D. Vogel, and J. Buchner ATP-binding properties of human Hsp90 J. Biol. Chem. 272 1997 18608 18613
49. Z. Weihua, S. Makela, L.C. Andersson, S. Salmi, S. Saji, J.I. Webster, E.V. Jensen, S. Nilsson, M. Warner, and J.A. Gustafsson A role for estrogen receptor beta in the regulation of growth of the ventral prostate Proc. Natl. Acad. Sci. U.S.A. 98 2001 6330 6335
50. M.O. Lee, E.O. Kim, H.J. Kwon, Y.M. Kim, H.J. Kang, H. Kang, and J.E. Lee Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90 Mol. Cell. Endocrinol. 188 2002 47 54
51. J.-M. Renoir, C. Radanyi, L.E. Faber, and E.E. Baulieu The non-DNA-binding heterooligomeric form of mammalian steroid hormone receptors contains a hsp90-bound 59-kiloDalton protein J. Biol. Chem. 265 1990 10740 10745
52. W.B. Pratt, and D.O. Toft Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery Exp. Biol. Med. (Maywood) 228 2003 111 133
53. T. Ratajczak, A. Carrello, P.J. Mark, B.J. Warner, R.J. Simpson, R.L. Moritz, and A.K. House The cyclophilin component of the unactivated estrogen receptor contains a tetratricopeptide repeat domain and shares identity with p59 (FKBP59) J. Biol. Chem. 268 1993 13187 13192
54. P. Kumar, P.J. Mark, B.K. Ward, R.F. Minchin, and T. Ratajczak Estradiol-regulated expression of the immunophilins cyclophilin 40 and FKBP52 in MCF-7 breast cancer cells Biochem. Biophys. Res. Commun. 284 2001 219 225
55. S.L. Schreiber, and G.R. Crabtree Immunophilins, ligands, and the control of signal transduction Harvey Lect. 91 1995 99 114
56. S. Hashemolhosseini, Y. Nagamine, S.J. Morley, S. Desrivieres, L. Mercep, and S. Ferrari Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability J. Biol. Chem. 273 1998 14424 14429
57. F.L. Luan, M. Hojo, M. Maluccio, K. Yamaji, and M. Suthanthiran Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy Transplantation 73 2002 1565 1572
58. M. Hojo, T. Morimoto, M. Maluccio, T. Asano, K. Morimoto, M. Lagman, T. Shimbo, and M. Suthanthiran Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530 534
59. G.J. Nabel A transformed view of cyclosporine Nature 397 1999 471 472